Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573712 | 0.93 | LMNA (0.64) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL23636489 | 0.93 | LMNA (0.64) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL23636429 | 0.93 | LMNA (0.64) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL23636477 | 0.93 | LMNA (0.64) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL23636502 | 0.93 | LMNA (0.64) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL25363728 | 0.93 | LMNA (0.64) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL6245784 | 0.93 | HTT (0.54) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL26813921 | 0.91 | TGM2 (0.53) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL591226 | 0.84 | L3MBTL1 (0.47) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL31122455 | 0.83 | P2RX7 (0.45) | LMNASMN1; SMN2L3MBTL1MAPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590673-A1 | FLUORESCENT PROBES FOR MAGL | F. Hoffmann-La Roche AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024061853-A1 | FLUORESCENT PROBES FOR MAGL | F. HOFFMANN-LA ROCHE AG (CH) | 2024-03-28 | — | — | WO | disclosed |
| WO-2017089890-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089895-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| US-6737416-B2 | THROMBOLYTIC AGENT HAVING HIGHER SAFETY | MEIJI SEIKA KAISHA LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-20030207804-A1 | Modified peptide nucleic acids | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| US-6620848-B2 | Antiarthritic agents, antihistamines, headaches | SMITHKLINE BEECHAM CORPORATION | 2003-09-16 | — | — | US | disclosed |
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| US-6576627-B1 | Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-1152004-B1 | Phosphonic acid derivatives having carboxypeptidase B inhibitory action | MEIJI SEIKA KAISHA (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6369272-B1 | ENZYME INHIBITORS OF AMIDINE ALKYL SULFIDE AMINOACIDS | GLAXOSMITHKLINE | 2002-04-09 | — | — | US | disclosed |
| US-20020010366-A1 | Nitric oxide synthase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-01-24 | — | — | US | disclosed |
| EP-1174434-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-0958277-B1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LTD (GB) | 2001-11-21 | — | — | EP | disclosed |
| EP-1152004-A1 | PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY | MEIJI SEIKA KAISHA LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
| EP-0958277-A1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998030537-A1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
| EP-0389437-B1 | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1995-05-24 | — | — | EP | disclosed |
| US-5128069-A | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1992-07-07 | — | — | US | disclosed |
| EP-0389437-A1 | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | CPB1, RNPEP, CPN1 | LMNA 2640/4885SMN1; SMN2 4505/4885L3MBTL1 440/4885 |
| US-20030207804-A1 | Modified peptide nucleic acids | NGLY1, PARN, NPPA | LMNA 628/4885SMN1; SMN2 1515/4885L3MBTL1 943/4885 |
| US-20020010366-A1 | Nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | LMNA 2211/4885SMN1; SMN2 2062/4885L3MBTL1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.